These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 30397789

  • 1. Long-term safety and tolerability of valsartan in children aged 6 to 17 years with hypertension.
    Lou-Meda R, Stiller B, Antonio ZL, Zielinska E, Yap HK, Kang HG, Tan M, Glazer RD, Valentin MA, Wang L.
    Pediatr Nephrol; 2019 Mar; 34(3):495-506. PubMed ID: 30397789
    [Abstract] [Full Text] [Related]

  • 2. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T, Smith TR, Glazer R, Wernsing M, Yen J, Jin J, Schneider H, Pospiech R.
    Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
    [Abstract] [Full Text] [Related]

  • 3. Effect of low-dose valsartan on proteinuria in normotensive immunoglobulin A nephropathy with minimal proteinuria: a randomized trial.
    Jo YI, Na HY, Moon JY, Han SW, Yang DH, Lee SH, Park HC, Choi HY, Lim SD, Kie JH, Lee YK, Shin SK.
    Korean J Intern Med; 2016 Mar; 31(2):335-43. PubMed ID: 26874511
    [Abstract] [Full Text] [Related]

  • 4. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.
    Chrysant SG, Murray AV, Hoppe UC, Dattani D, Patel S, Hsu H, Zhang J.
    Curr Med Res Opin; 2008 Apr; 24(4):1039-47. PubMed ID: 18307835
    [Abstract] [Full Text] [Related]

  • 5. Effect of telmisartan on blood pressure control and kidney function in hypertensive, proteinuric patients with chronic kidney disease.
    Rysavá R, Tesar V, Merta M, Czech Group for the Study of Glomerulonephritis.
    Blood Press Monit; 2005 Aug; 10(4):207-13. PubMed ID: 16077267
    [Abstract] [Full Text] [Related]

  • 6. Losartan and enalapril are comparable in reducing proteinuria in children.
    Webb NJ, Shahinfar S, Wells TG, Massaad R, Gleim GW, Santoro EP, Sisk CM, Lam C.
    Kidney Int; 2012 Oct; 82(7):819-26. PubMed ID: 22739977
    [Abstract] [Full Text] [Related]

  • 7. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
    Esnault VL, Ekhlas A, Nguyen JM, Moranne O.
    Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
    [Abstract] [Full Text] [Related]

  • 8. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.
    Circulation; 2009 Oct 20; 120(16):1577-84. PubMed ID: 19805651
    [Abstract] [Full Text] [Related]

  • 9. Telmisartan in patients with mild/moderate hypertension and chronic kidney disease.
    Sharma AM, Hollander A, Köster J, Efficacy and Safety in Patients with Renal Impairment, treated with Telmisartan (ESPRIT) Study Group.
    Clin Nephrol; 2005 Apr 20; 63(4):250-7. PubMed ID: 15847251
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of valsartan in children aged 1-5 years with hypertension, with or without chronic kidney disease: a randomized, double-blind study followed by open-label phase.
    Jankauskiene A, Drozdz D, Wasilewska A, de Paula-Bernardes R, Glazer R, Valentin M, Tan M, Chiang Y, Bapatla K.
    Curr Med Res Opin; 2021 Dec 20; 37(12):2113-2122. PubMed ID: 34543161
    [Abstract] [Full Text] [Related]

  • 11. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
    Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF.
    J Hypertens; 2000 Jan 20; 18(1):89-95. PubMed ID: 10678548
    [Abstract] [Full Text] [Related]

  • 12. Aliskiren add-on therapy effectively reduces proteinuria in chronic kidney disease: an open-label prospective trial.
    Wu MT, Tung SC, Hsu KT, Lee CT.
    J Renin Angiotensin Aldosterone Syst; 2014 Sep 20; 15(3):271-7. PubMed ID: 23223162
    [Abstract] [Full Text] [Related]

  • 13. Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy.
    Bomback AS, Rekhtman Y, Klemmer PJ, Canetta PA, Radhakrishnan J, Appel GB.
    J Am Soc Hypertens; 2012 Sep 20; 6(5):338-45. PubMed ID: 22995802
    [Abstract] [Full Text] [Related]

  • 14. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
    Galle J, Schwedhelm E, Pinnetti S, Böger RH, Wanner C, VIVALDI investigators.
    Nephrol Dial Transplant; 2008 Oct 20; 23(10):3174-83. PubMed ID: 18450829
    [Abstract] [Full Text] [Related]

  • 15. Effects of valsartan on progression of kidney disease in Japanese hypertensive patients with advanced, predialysis, chronic kidney disease: Kanagawa Valsartan Trial (KVT).
    Yasuda T, Endoh M, Suzuki D, Yoshimura A, Ideura T, Tamura K, Kamata K, Toya Y, Umemura S, Kimura K, KVT Study Group.
    Hypertens Res; 2013 Mar 20; 36(3):240-6. PubMed ID: 23154591
    [Abstract] [Full Text] [Related]

  • 16. Efficacy, safety and tolerability of valsartan 80 mg compared to irbesartan 150 mg in hypertensive patients on long-term hemodialysis (VALID study).
    Leidig M, Bambauer R, Kirchertz EJ, Szabã T, Handrock R, Leinung D, Baier M, Schmieder RE.
    Clin Nephrol; 2008 Jun 20; 69(6):425-32. PubMed ID: 18538118
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of 30-mg fimasartan for the treatment of patients with mild to moderate hypertension: an 8-week, multicenter, randomized, double-blind, phase III clinical study.
    Youn JC, Ihm SH, Bae JH, Park SM, Jeon DW, Jung BC, Park TH, Lee NH, Song JM, Yoon YW, Shin ES, Sung KC, Jung IH, Pyun WB, Joo SJ, Park WJ, Shin JH, Kang SM.
    Clin Ther; 2014 Oct 01; 36(10):1412-21. PubMed ID: 25092393
    [Abstract] [Full Text] [Related]

  • 18. Comparison of efficacy and safety between benidipine and hydrochlorothiazide in fosinopril-treated hypertensive patients with chronic kidney disease: protocol for a randomised controlled trial.
    Xue C, Zhou C, Yang B, Lv J, Dai B, Yu S, Wang Y, Zhao G, Mei C.
    BMJ Open; 2017 Feb 24; 7(2):e013672. PubMed ID: 28237959
    [Abstract] [Full Text] [Related]

  • 19. Real-life effectiveness, safety, and tolerability of amlodipine/valsartan or amlodipine/valsartan/hydrochlorothiazide single-pill combination in patients with hypertension from Pakistan.
    Khan W, Moin N, Iktidar S, Sakrani J, Abid R, Afzal J, Maheshwary N, Kumar K, Siddiqi A, Qadir M.
    Ther Adv Cardiovasc Dis; 2014 Apr 24; 8(2):45-55. PubMed ID: 24562476
    [Abstract] [Full Text] [Related]

  • 20. Clinical Effectiveness, Safety and Tolerability of Amlodipine/Valsartan in Hypertensive Patients: the Indonesian Subset of the EXCITE Study.
    Setiawati A, Kalim H, Abdillah A.
    Acta Med Indones; 2015 Jul 24; 47(3):223-33. PubMed ID: 26586388
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.